LWPC
CNCR

Legacy Wealth Partners (California)’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Legacy Wealth Partners (California)’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$525K Sell
16,464
-4,008
-20% -$121K 0.29% 66
2021
Q1 		$613K Buy
20,472
+5,042
+33% +$164K 0.36% 59
2020
Q4 		$489K Buy
15,430
+6,161
+66% +$185K 0.31% 59
2020
Q3 		$255K Sell
9,269
-620
-6% -$16.6K 0.18% 80
2020
Q2 		$268K Buy
+9,889
New +$243K 0.2% 83

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Legacy Wealth Partners (California)'s CNCR Position: Q2 2021 in Review

Legacy Wealth Partners (California) reduced its ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) stake by 20% in Q2 2021, selling an estimated $121K and leaving 16,464 shares worth $525K. The position accounts for 0.29% of the portfolio, ranked #66.

Legacy Wealth Partners (California) first reported a position in CNCR in Q2 2020 and has held it in 5 quarters since. The position peaked at $613K in Q1 2021. 21 funds tracked by Wall St. Rank hold CNCR as of Q2 2021.

  • Legacy Wealth Partners (California) held 16,464 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $525K as of Q2 2021.
  • Legacy Wealth Partners (California) sold 4,008 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2021, an estimated $121K.
  • ETF Series Solutions Trust Range Cancer Therapeutics ETF made up 0.29% of Legacy Wealth Partners (California)'s portfolio in Q2 2021, its #66 holding.
  • Legacy Wealth Partners (California) first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2020 and has held it in 5 quarters since.
  • Legacy Wealth Partners (California)'s ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $613K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2021.

Based on Legacy Wealth Partners (California)'s 13F filing for Q2 2021, filed 16 Aug 2021.